PXMD — Kuvatris Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Paxmedica Completes Hat-301 Registrational Trial For Pax-101
Brief: Paxmedica, Inc. Provides First Quarter 2023 Business Update Phase 3 Hat-301 Top Line Results Expected In Second Half 2023
Brief: PaxMedica Inc Files For Resale Of Up To 3.4 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Paxmedica Inc - Files For Offering For Up To 13.1 mln shares Of Common Stock
Brief: PaxMedica Inc- On December 6, 2022, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Brief: Paxmedica Provides Business Update And Reports Third Quarter 2022 Financial Results
Brief: Paxmedica Initiates Clinical Program To Advance Pax-101 Towards FDA Submission
Brief: PaxMedica Provides Corporate Update After IPO
Brief: Paxmedica Inc Announces Pricing Of Initial Public Offering